Invesco
RPRX icon

Invesco’s Royalty Pharma RPRX Stock Holding History

Invesco’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$237M Buy
4,232,577
+480,178
+13% +$25M 0.02% 677
2026
Q1 		$180M Buy
3,752,399
+2,250,228
+150% +$98.6M 0.02% 703
2025
Q4 		$58M Sell
1,502,171
-87,345
-5% -$3.33M 0.01% 1028
2025
Q3 		$56.1M Buy
1,589,516
+30,138
+2% +$1.09M 0.01% 1040
2025
Q2 		$56.2M Buy
1,559,378
+274,960
+21% +$9.11M 0.01% 1017
2025
Q1 		$40M Buy
1,284,418
+326,525
+34% +$10.3M 0.01% 1126
2024
Q4 		$24.4M Buy
957,893
+238,508
+33% +$6.32M ﹤0.01% 1388
2024
Q3 		$20.4M Sell
719,385
-1,017,136
-59% -$28.2M ﹤0.01% 1457
2024
Q2 		$45.8M Buy
1,736,521
+1,062,833
+158% +$29.5M 0.01% 1048
2024
Q1 		$20.5M Buy
673,688
+16,833
+3% +$496K ﹤0.01% 1441
2023
Q4 		$18.5M Buy
656,855
+46,849
+8% +$1.29M ﹤0.01% 1453
2023
Q3 		$16.6M Sell
610,006
-79,942
-12% -$2.37M ﹤0.01% 1443
2023
Q2 		$21.2M Sell
689,948
-23,219
-3% -$786K 0.01% 1338
2023
Q1 		$25.7M Sell
713,167
-2,169,823
-75% -$80.5M 0.01% 1226
2022
Q4 		$114M Sell
2,882,990
-247,861
-8% -$10.3M 0.03% 671
2022
Q3 		$126M Buy
3,130,851
+479,358
+18% +$20.5M 0.04% 582
2022
Q2 		$111M Buy
2,651,493
+1,968,126
+288% +$80.7M 0.03% 650
2022
Q1 		$26.6M Buy
683,367
+139,768
+26% +$5.49M 0.01% 1319
2021
Q4 		$21.7M Sell
543,599
-84,611
-13% -$3.29M 0.01% 1501
2021
Q3 		$22.7M Sell
628,210
-65,308
-9% -$2.54M 0.01% 1486
2021
Q2 		$28.4M Buy
693,518
+30,885
+5% +$1.31M 0.01% 1389
2021
Q1 		$28.9M Buy
662,633
+451,898
+214% +$21.4M 0.01% 1323
2020
Q4 		$10.5M Sell
210,735
-621,386
-75% -$26.4M ﹤0.01% 1776
2020
Q3 		$35M Buy
832,121
+82,121
+11% +$3.52M 0.01% 1059
2020
Q2 		$36.4M Buy
+750,000
New +$37.1M 0.01% 1042

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's RPRX Position: Q2 2026 in Review

Invesco increased its Royalty Pharma (RPRX) stake by 13% in Q2 2026, buying an estimated $25M and bringing the position to 4,232,577 shares worth $237M. The position accounts for 0.02% of the portfolio, ranked #677.

Invesco first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Invesco held 4,232,577 shares of Royalty Pharma worth $237M as of Q2 2026.
  • Invesco bought 480,178 Royalty Pharma shares in Q2 2026, an estimated $25M.
  • Royalty Pharma made up 0.02% of Invesco's portfolio in Q2 2026, its #677 holding.
  • Invesco first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.